Modulation of the functional connectome in major depressive disorder by ketamine therapy

被引:23
|
作者
Sahib, Ashish K. [1 ]
Loureiro, Joana R. [1 ]
Vasavada, Megha [1 ]
Anderson, Cole [1 ]
Kubicki, Antoni [1 ]
Wade, Benjamin [1 ]
Joshi, Shantanu H. [1 ]
Woods, Roger P. [1 ,2 ]
Congdon, Eliza [2 ]
Espinoza, Randall [2 ]
Narr, Katherine L. [1 ,2 ]
机构
[1] Univ Calif Los Angeles, Dept Neurol, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA
基金
美国国家卫生研究院;
关键词
Functional connectivity; ketamine; major depression; salience network; INDEPENDENT COMPONENT ANALYSIS; TREATMENT-RESISTANT DEPRESSION; DEFAULT-MODE NETWORK; RANDOMIZED-TRIAL; BRAIN ACTIVITY; RATING-SCALE; CONNECTIVITY; METAANALYSIS; CORTEX; CEREBELLAR;
D O I
10.1017/S0033291720004560
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Subanesthetic ketamine infusion therapy can produce fast-acting antidepressant effects in patients with major depression. How single and repeated ketamine treatment modulates the whole-brain functional connectome to affect clinical outcomes remains uncharacterized. Methods Data-driven whole brain functional connectivity (FC) analysis was used to identify the functional connections modified by ketamine treatment in patients with major depressive disorder (MDD). MDD patients (N = 61, mean age = 38, 19 women) completed baseline resting-state (RS) functional magnetic resonance imaging and depression symptom scales. Of these patients, n = 48 and n = 51, completed the same assessments 24 h after receiving one and four 0.5 mg/kg intravenous ketamine infusions. Healthy controls (HC) (n = 40, 24 women) completed baseline assessments with no intervention. Analysis of RS FC addressed effects of diagnosis, time, and remitter status. Results Significant differences (p < 0.05, corrected) in RS FC were observed between HC and MDD at baseline in the somatomotor network and between association and default mode networks. These disruptions in FC in MDD patients trended toward control patterns with ketamine treatment. Furthermore, following serial ketamine infusions, significant decreases in FC were observed between the cerebellum and salience network (SN) (p < 0.05, corrected). Patient remitters showed increased FC between the cerebellum and the striatum prior to treatment that decreased following treatment, whereas non-remitters showed the opposite pattern. Conclusion Results support that ketamine treatment leads to neurofunctional plasticity between distinct neural networks that are shown as disrupted in MDD patients. Cortico-striatal-cerebellar loops that encompass the SN could be a potential biomarker for ketamine treatment.
引用
收藏
页码:2596 / 2605
页数:10
相关论文
共 50 条
  • [41] The concurrent disturbance of dynamic functional and structural brain connectome in major depressive disorder: the prefronto-insular pathway
    Zhang, Huifeng
    Palaniyappan, Lena
    Wu, Yan
    Cong, Enchao
    Wu, Chuangxin
    Ding, Lei
    Jin, Feng
    Qiu, Meihui
    Huang, Yueqi
    Wu, Ye
    Wang, Jinhong
    Ying, Shihui
    Peng, Daihui
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2020, 274 : 1084 - 1090
  • [42] Efficacy of different doses of ketamine as a bolus in major depressive disorder
    Kheirkhah, Farzan
    Tayyebi, Gooya
    Rabiee, Seyed Mozaffar
    Moghadamnia, Ali-Akbar
    Bijani, Ali
    [J]. CASPIAN JOURNAL OF INTERNAL MEDICINE, 2018, 9 (03) : 220 - 227
  • [43] Evaluation of Opioid Modulation in Major Depressive Disorder
    Elliot Ehrich
    Ryan Turncliff
    Yangchun Du
    Richard Leigh-Pemberton
    Emilio Fernandez
    Reese Jones
    Maurizio Fava
    [J]. Neuropsychopharmacology, 2015, 40 : 1448 - 1455
  • [44] A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
    Lapidus, Kyle A. B.
    Levitch, Cara F.
    Perez, Andrew M.
    Brallier, Jess W.
    Parides, Michael K.
    Soleimani, Laili
    Feder, Adriana
    Iosifescu, Dan V.
    Charney, Dennis S.
    Murrough, James W.
    [J]. BIOLOGICAL PSYCHIATRY, 2014, 76 (12) : 970 - 976
  • [45] Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder
    Covvey, Jordan R.
    Crawford, Alexis Noble
    Lowe, Denise K.
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (01) : 117 - 123
  • [46] Evaluation of Opioid Modulation in Major Depressive Disorder
    Ehrich, Elliot
    Turncliff, Ryan
    Du, Yangchun
    Leigh-Pemberton, Richard
    Fernandez, Emilio
    Jones, Reese
    Fava, Maurizio
    [J]. NEUROPSYCHOPHARMACOLOGY, 2015, 40 (06) : 1448 - 1455
  • [47] Effect of Ketamine Treatment on Amygdala Responsivity in Major Depressive Disorder
    Loureiro, Joana
    Leaver, Amber
    Vasavada, Megha
    Kubicki, Antoni
    Joshi, Shantanu
    Njau, Stephanie
    Wade, Benjamin
    Espinoza, Randall
    Congdon, Eliza
    Narr, Katherine
    [J]. BIOLOGICAL PSYCHIATRY, 2018, 83 (09) : S291 - S291
  • [48] REPEATED KETAMINE TREATMENT FOR COMORBID MAJOR DEPRESSIVE DISORDER AND ALCOHOL USE DISORDER
    Yoon, G.
    Ralevski, E.
    Abdallah, C. G.
    Arias, A. J.
    Limoncelli, D.
    Newcomb, J.
    Jane, J. S.
    Sofuoglu, M.
    Krystal, J. H.
    Petrakis, I. L.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2016, 40 : 97A - 97A
  • [49] Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
    Rong, Carola
    Park, Caroline
    Rosenblat, Joshua D.
    Subramaniapillai, Mehala
    Zuckerman, Hannah
    Fus, Dominika
    Lee, Yena L.
    Pan, Zihang
    Brietzke, Elisa
    Mansur, Rodrigo B.
    Cha, Danielle S.
    Lui, Leanna M. W.
    McIntyre, Roger S.
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2018, 15 (04):
  • [50] NALTREXONE PLUS KETAMINE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER AND ALCOHOL USE DISORDER
    Yoon, G.
    Ralevski, E.
    Arias, A. J.
    Limoncelli, D.
    Newcomb, J.
    Levy, L.
    Jane, J. S.
    Krystal, J. H.
    Petrakis, I. L.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 42 : 236A - 236A